Laws and Labels: A Regulatory View of Biosimilars
Now that the first biosimilar product has been approved by FDA, healthcare professionals need to get up to speed on the evolving rules and policies that will separate biosimilars from interchangeable biologics and branded products. Join healthcare legal expert Erika Lietzan for a webinar examining the latest from the FDA on labeling biosimilars, the scientific and legal differences between biosimilars and other products, and the potential impact on prescribing and dispensing practices.
You may also like:
NCPDP, the standards development organization focused on the pharmacy sector, just wrapped up its annual business and technology conference, which immediately followed its quarterly technical ...
Opioid analgesics remain the first-line treatment for moderate-to-severe acute pain in emergency departments. But a study published in JAMA 2017 showed tha...
While studies confirm that prescription drug monitoring programs (PDMPs) do help states reduce misuse and diversion of opioid drug products, many professionals and research data still report variable benefits, inconsistent usag...
Stay in the Know
Sign up to start receiving notifications via email of our upcoming webinars!